Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational studyFederica Martella, Eloise Beggiato, Irene Urbino et al.|Annals of Hematology|2022Cited by 38
Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021Irene Urbino, Marco Cerrano, Carolina Secreto et al.|Cancers|2021Cited by 21
Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic ChallengesMatteo Olivi, Marco Cerrano, Federica Di Biase et al.|Current Treatment Options in Oncology|2023Cited by 20
Validation of <scp>SIE</scp>/<scp>SIES</scp>/<scp>GITMO</scp> consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclaxVincenzo Apolito, Felicetto Ferrara, Giulia Arrigo et al.|British Journal of Haematology|2023Cited by 6
Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experienceIrene Urbino, Marco Cerrano, Carolina Secreto et al.|Leukemia Research|2023Cited by 2